Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target Maximize Your Portfolio with Data Driven ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy ...

SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 128.8% in the 4th quarter, according to the company in its most recent filing ...

Stifel analysts confirmed their Buy rating on Denali Therapeutics Inc. (NASDAQ:DNLI) with a steady price target of $37.00. According to InvestingPro data, analysts maintain a Strong Buy consensus with ...

Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.

Did you know that we deliver to 130 countries or regions and offer a range of delivery options to suit you wherever you are in the world? Find out more Sign up once to our Selfridges+ service and you ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Roche Holding AG Akt-0.56% CHF240.64B ...

Roche Holding AG Akt 2.44% CHF235.6B ...